Characterization of metabolites of a NK1 receptor antagonist, CJ-11,972, in human liver microsomes and recombinant human CYP isoforms by liquid chromatography/tandem mass spectrometry

Rapid Communications in Mass Spectrometry

Volumn 21, Issue 17, 2007, Pages 2822-2832

  Prakash, Chandra ^a   Lin, Jinyan ^a   Colizza, Kevin ^a   Miao, Zhuang ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDES; BIOMOLECULES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; OXIDATION;

DEMETHYLATION; HUMAN LIVER MICROSOMES; IN-VITRO; ISOFORMS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY-MASS SPECTROMETRIES; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; RECEPTOR ANTAGONISTS; TANDEM MASS SPECTROMETRY; TANDEM-MASS SPECTROMETRY;

METABOLITES;

(2-BENZHYDRYL-1-AZA-BICYCLO(2.2.2)OCT-3-YL)-(5-TERT-BUTYL-2-METHOXYBENZYL)AMINE; (2 BENZHYDRYL 1 AZA BICYCLO(2.2.2)OCT 3 YL) (5 TERT BUTYL 2 METHOXYBENZYL)AMINE; BENZHYDRYL DERIVATIVE; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; FUSED HETEROCYCLIC RINGS; NEUROKININ 1 RECEPTOR; RECOMBINANT PROTEIN;

ARTICLE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CELL; LIVER MICROSOME; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; ULTRASTRUCTURE;

BENZHYDRYL COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; HEPATOCYTES; HUMANS; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; RECEPTORS, NEUROKININ-1; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 34548166821     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.3153     Document Type: Article

References (14)

1. Adams PF, Marano MA. Vital Health Stat. 1995; 10: 81.
2. Beggs Si, Salter MW. Drug Develop. Res. 2006; 67: 289.
3. Galer BS. Adv. Pharmacol. Treatment. Neurol. 1995; (Suppl 9): s17.
4. Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, Twissell DJ, Ward P. Eur. J. Pharmacol. 1996; 65: 45.
5. Grelot L, Dapzol J, Esteve E, Frugiere A, Bianchi AL, Sheldrick RL, Gardner CJ, Ward P. Br. J. Pharmacol. 1998; 124: 1643.
6. Diemunsch P, Grelot L. Drugs 2000; 60: 533.
7. Gonsalves SF, Watson JW, Ashton CA. Eur. J. Pharmacol. 1996; 305: 181.
8. Bachmann KA, Ghosh R. Curr. Drug Metab. 2001; 3: 299.
9. Baranczewski P, Stanczak A, Kautianinen A, Sandin P, Edlund P-O. Pharmacol. Rep. 2006; 58: 341.
10. Kamel A, Prakash C. Curr. Drug Metab. 2006; 7: 837.
11. Prakash C, Shaffer C, Nedderman A. Mass Spectrom. Rev. 2007; 26: 340.
12. Zandi KS, Miller SA, McCarthy KE, Massefski WW, Kamel A. In Isotope Production and Applications in the 21st Century, Proc. 3rd Int. Conf. on Isotopes, Vancouver, BC, Canada, Sept. 6-10, 1999.
13. Omura T, Sato R. J. Biol. Chem. 1964; 239: 3137.
14. Kamm JJ, Szuna AJ. Pharmacol. Exp. Ther. 1973; 184: 729.